Dr. Mike Myers has spent nearly 30 years in the pharma industry contributing to the discovery and development of new drugs. He has led drug discovery teams in the pursuit of innovative treatments for cancer, CNS, Infectious and cardiovascular diseases. Across these areas of significant need, Dr. Myers has contributed as an inventor on more than 35 patents. Dr. Myers has also led efforts in evaluating new lead generation technologies, predictive ADMET and computational chemistry approaches and led a significant effort at Lilly to optimize Lead generation processes in early drug discovery. Dr. Myers has also held responsibilities as Sr. Director of Project Management and was engaged in project and portfolio management across Discovery and Development. For the last ~9 years, Mike’s main responsibilities within the External Innovation team at Eli Lilly & Company includes leading scientific & technical Due Diligence activities in support of in-license/acquisition, out-license and strategic partnering activities. In addition, for the last several years Dr. Myers has also been very involved in Lilly’s academic outreach by participating in external panel reviews for translational research (The Rockefeller Univ., Wash. U., OSU and others) by representing Lilly on Industrial Advisory Boards (e.g, the Univ. of Texas system) and has been working in partnership with several of Lilly’s strategic VC partners in reviewing potential academic sourced opportunities leading to the creation of new companies.